Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
D DERMATOLOGICALS
D11 OTHER DERMATOLOGICAL PREPARATIONS
D11A OTHER DERMATOLOGICAL PREPARATIONS
D11AH Agents for dermatitis, excluding corticosteroids
D11AH08 Abrocitinib
D11400 Abrocitinib (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Abrocitinib
D11400 Abrocitinib (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
44 Allergic agents
449 Miscellaneous
4490 Miscellaneous
D11400 Abrocitinib (JAN/USAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
D11400 Abrocitinib
Dermatological agent
DG03243 Atopic dermatitis agent
D11400 Abrocitinib
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
D11400 Abrocitinib
DG01639 CYP2C19 substrate
D11400 Abrocitinib
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11400 Abrocitinib
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11400 Abrocitinib
Dermatological agent
DG03243 Atopic dermatitis agent
D11400 Abrocitinib
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11400 Abrocitinib (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11400
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11400
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11400
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11400
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11400
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D11400